Vident Investment Advisory, LLC Gilead Sciences, Inc. Transaction History

Vident Investment Advisory, LLC

$0
Q3 2023

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $5.13 Million - $5.85 Million	-67,461 Reduced 37.72%	111,365 $8.58 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $7.57 Million - $8.62 Million	97,875 Added 120.91%	178,826 $14.8 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $2.34 Million - $3.36 Million	-37,596 Reduced 31.71%	80,951 $6.95 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $259,773 - $296,727	4,363 Added 3.82%	118,547 $6.92 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $851,831 - $959,417	-14,758 Reduced 11.45%	114,184 $7.06 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $2.45 Million - $3.07 Million	42,292 Added 48.81%	128,942 $7.67 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $876,658 - $995,023	-13,512 Reduced 13.49%	86,650 $6.29 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $1.15 Million - $1.24 Million	16,963 Added 20.39%	100,162 $7 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $366,348 - $400,288	5,772 Added 7.45%	83,199 $5.73 Million
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $263,280 - $300,402	-4,388 Reduced 5.36%	77,427 $5.01 Million
Q4 2020 Feb 08, 2021	BUY	$56.65 - $64.55 $721,154 - $821,721	12,730 Added 18.43%	81,815 $4.77 Million
Q3 2020 Nov 12, 2020	BUY	$62.1 - $78.08 $1.08 Million - $1.35 Million	17,337 Added 33.5%	69,085 $4.37 Million
Q2 2020 Jul 28, 2020	SELL	$72.34 - $84.0 $1.65 Million - $1.92 Million	-22,868 Reduced 30.65%	51,748 $3.98 Million
Q2 2020 Jul 17, 2020	BUY	$72.34 - $84.0 $1.93 Million - $2.24 Million	26,703 Added 55.73%	74,616 $5.74 Million
Q1 2020 May 12, 2020	BUY	$62.63 - $80.22 $129,518 - $165,894	2,068 Added 4.51%	47,913 $3.58 Million
Q4 2019 Feb 11, 2020	BUY	$61.62 - $67.78 $139,384 - $153,318	2,262 Added 5.19%	45,845 $2.98 Million
Q3 2019 Nov 13, 2019	BUY	$62.51 - $69.0 $86,826 - $95,841	1,389 Added 3.29%	43,583 $2.76 Million
Q2 2019 Aug 12, 2019	SELL	$61.87 - $69.38 $98,373 - $110,314	-1,590 Reduced 3.63%	42,194 $2.85 Million
Q1 2019 May 08, 2019	BUY	$62.53 - $70.05 $369,802 - $414,275	5,914 Added 15.62%	43,784 $2.85 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $376,437 - $491,222	-6,218 Reduced 14.1%	37,870 $2.37 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $3.1 Million - $3.43 Million	-43,421 Reduced 49.62%	44,088 $3.4 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $816,255 - $952,130	12,581 Added 16.79%	87,509 $6.2 Million
Q1 2018 May 14, 2018	BUY	$72.84 - $88.8 $446,363 - $544,166	6,128 Added 8.91%	74,928 $5.59 Million
Q4 2017 Feb 15, 2018	BUY	$71.15 - $83.52 $1.41 Million - $1.66 Million	19,833 Added 40.5%	68,800 $4.93 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $3.53 Million - $4.19 Million	48,967	48,967 $3.97 Million

Others Institutions Holding GILD

# of Institutions

1,893

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.04M

Black Rock Inc. New York, NY

121M
Shares

$10.6 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.2 Billion
0.15% of portfolio
Capital World Investors Los Angeles, CA

76.2M
Shares

$6.72 Billion
0.88% of portfolio
Capital Research Global Investors Los Angeles, CA

60.4M
Shares

$5.32 Billion
0.94% of portfolio
State Street Corp Boston, MA

59.3M
Shares

$5.23 Billion
0.18% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Account